Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

NCT05659056 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pyrotinib, trastuzumab, paclitaxel-albumin

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]